Ethnic Differences in Mechanisms of Action of Dupilumab

Prior treatment

• Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
• Confirmed or suspected coronavirus disease 2019 (COVID-19) infection within 4 weeks before the screening or baseline visit
• Received COVID-19 vaccination within 4 weeks before baseline visit
• Previous treatment with dupilumab
• Planned or expected major surgical procedure during the study
• Currently participating or participated in any other study of a drug or device, within the past 8 weeks before the screening visit, or is in an exclusion period (if verifiable) from a previous study

Other illness

• Subjects meeting 1 or more of the following criteria at screening or baseline:
  • Had an exacerbation of asthma requiring hospitalization in the preceding 12 months.
  • Reporting asthma that has not been well-controlled (ie, symptoms occurring on \>2 days per week, nighttime awakenings 2 or more times per week, or some interference with normal activities) during the preceding 3 months
  • Asthma Control Test (ACT) \< 19 (only for subjects with a history of asthma).
  • Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis.
• History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the baseline visit
• History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, i.e., monoclonal antibody) or to lidocaine
• Known active or latent tuberculosis (TB) infection
• Known or suspected immunosuppression or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment
• History of or current confounding skin condition (i.e., Netherton syndrome, psoriasis, cutaneous T-cell lymphoma \[mycosis fungoides or Sezary syndrome\], contact dermatitis, chronic actinic dermatitis, dermatitis herpetiformis)
• History of alcohol or substance abuse within 6 months of the screening
• History of poor wound healing or keloid formation

Lab values

• Pregnant women (positive serum pregnancy test result at the screening visit or positive urine pregnancy test at the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study

Other

• Body weight less than 30 kilogram

• Established diagnosis of AD for at least 2 years before the screening visit and confirmed according to the American Academy of Dermatology Consensus Criteria at the time of the screening visit
• Moderate-to-severe AD with involvement \> 10% of body-surface-area (BSA) and investigator global assessment (IGA) score 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits
• Female subjects of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to commit to true abstinence throughout the study and for 12 weeks after the last study drug injection or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection
• Subject willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol